ReviewParasites & vectors2024
Echinococcus granulosus sensu lato control measures: a specific focus on vaccines for both definitive and intermediate hosts.
Review in Parasites & vectors, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Spatio-temporal dynamics, trend analysis, and incidence prediction of echinococcosis in Xinjiang, China (2005-2024).BMC public health · 2026Article
- Molecular evidence of Echinococcus canadensis (G6/G7) predominance in Mongolian livestock and its implications for control.PLoS neglected tropical diseases · 2026Article
- Prevalence and Genetic Diversity ofBiology · 2026Article
- Molecular characterization ofOpen veterinary journal · 2026Article
- A multicenter hospital-based analysis of cystic Echinococcosis in Afghanistan: Filling a National data gap.PLoS neglected tropical diseases · 2026Observational
- Molecular characterization and functional effect on canie peripheral blood mononuclear cells of phosphoglycerate kinase from Echinococcus granulosus.Parasitology research · 2026Article
- Enhancing hydatid cysts diagnosis utilizing cell-free DNA as a sensitive biomarker forHelminthologia · 2026Article
- Geographic, demographic and economic burden of human cystic echinococcosis in Italy based on hospital discharge records (2015-2022).PLoS neglected tropical diseases · 2026Article
- Three decades of research on molecular genetic characteristics of Echinococcus spp.: a bibliometric study.Folia parasitologica · 2026Review
- Genetic detection and phylogenetic assessment of multiple molecular markers ofOpen veterinary journal · 2026Article
- Molecular characterization of Echinococcus species causing human cystic echinococcosis in Algeria: predominance of Echinococcus granulosus sensu stricto.Parasite (Paris, France) · 2026Article
- Effects of recombinantFrontiers in cellular and infection microbiology · 2026Article
- Effect of antiserum against recombinant EGr_09888 on the in vitro development of Echinococcus granulosus protoscoleces.Parasitology research · 2025Article
- Oral administration of recombinant Bacillus subtilis spores induces protective immunity against Echinococcus granulosus infection in dogs.Parasites & vectors · 2025Article
- Cocktail vaccine induces immunoprotection and modulates the fecal microbiota in dogs against Echinococcus granulosus infection.NPJ vaccines · 2025Article
- Breaking the Cycle of Echinococcosis: A Mathematical Modeling Approach.Tropical medicine and infectious disease · 2025Article
- Development and protective efficacy of multi-epitope vaccine FL46 against cystic echinococcosis.Frontiers in immunology · 2025Article
- Diagnostic utility of hematological and biochemical markers for cystic echinococcosis in Tibetan patients of Sichuan, China.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Echinococcosis, a neglected zoonotic disease caused by Echinococcus tapeworms, presents significant public health challenges worldwide. Cystic and alveolar echinococcosis has substantial health and economic impacts, necessitating effective prevention and control strategies. The present review provides a framework to expand our knowledge regarding key components of echinococcosis prevention and control, including phases, options, targets and available tools as well as current gaps and challenges in the field. Furthermore, we discuss the progress made in developing vaccines for the intermediate and definitive hosts and review the limitations and obstacles in vaccine development for definitive hosts. Abundant information is available on various aspects of the Echinococcus vaccine in sheep. Livestock vaccination effectively reduces Echinococcus transmission to sheep, offering a feasible control measure in intermediate hosts. However, vaccine development for the definitive host, i.e. dogs, exhibits significant challenges. Information gaps regarding the immune-mediated protective responses in dogs, repeatability of results, factors influencing the immune response, reinfection resistance, potential age-related decreases in worm burden and factors associated with the antifecundity effect are key challenges that should be addressed in canine vaccine development, and research collaboration, innovative technologies, and a deeper understanding of transmission dynamics are crucial. Multisectoral coordination under the One Health framework, with long-term political commitment and national and international cooperation, is critical for effective control in endemic areas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.